financetom
Business
financetom
/
Business
/
Blackstone to Acquire Hipgnosis Song Fund for $1.57 Billion, Beating Concord Chorus Bid
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Blackstone to Acquire Hipgnosis Song Fund for $1.57 Billion, Beating Concord Chorus Bid
Apr 29, 2024 4:27 AM

07:10 AM EDT, 04/29/2024 (MT Newswires) -- Blackstone (BX) is set to acquire the UK's Hipgnosis Song Fund for $1.57 billion in cash, the companies said Monday.

The boards of directors of Hipgnosis, whose assets include the catalogs of many famous artists, and of Blackstone subsidiary Lyra Bidco, said in a regulatory filing that they agreed to a $1.30 per share price that is 4% above the $1.25 price offered by rival Concord Chorus and 48.1% over the company's April 17 closing price.

Hipgnosis said in a regulatory filing "that the terms of the acquisition represent an attractive premium for Hipgnosis shareholders" over Concord's final offer.

The deal, expected to close in Q3, is conditional on shareholder approval and other customary conditions, the filing said.

Blackstone is a majority owner of Hipgnosis' investment adviser HSM and claims an option to buy the fund's 40,000 songs catalog should that relationship be severed. In arguing for the sale, Hipgnosis' board cited Blackstone's tendency "to build and grow the businesses in which it invests" and its "particularly strong focus on the media and entertainment sectors."

Price: 122.47, Change: -0.02, Percent Change: -0.02

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Elevai Labs, Yuva Biosciences File 2 Hair Treatment Patents
Elevai Labs, Yuva Biosciences File 2 Hair Treatment Patents
Aug 29, 2024
08:03 AM EDT, 08/28/2024 (MT Newswires) -- Elevai Labs ( ELAB ) said Wednesday it has filed two hair and scalp vitality patents in collaboration with Yuva Biosciences. The first patent is for a skin, scalp, and hair improvement treatment while the second patent covers the use of exosomes as a delivery system, the company said. Price: 0.3101, Change: -0.01,...
--India's Regulator Approves Disney-Reliance Media Merger
--India's Regulator Approves Disney-Reliance Media Merger
Aug 29, 2024
07:32 AM EDT, 08/28/2024 (MT Newswires) -- Price: 90.93, Change: +0.03, Percent Change: +0.03 ...
Neurocrine Biosciences' Schizophrenia Drug Shows 'Significant' Symptom Reduction in Phase 2 Trial
Neurocrine Biosciences' Schizophrenia Drug Shows 'Significant' Symptom Reduction in Phase 2 Trial
Aug 29, 2024
08:07 AM EDT, 08/28/2024 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Wednesday a phase 2 dose-finding study of its investigational drug NBI-1117568 in adult patients with schizophrenia showed 'statistically significant' reduction in symptom severity. The tests also demonstrated 'statistically significant improvement' in additional scales for schizophrenia symptoms, Neurocrine said. The test's goal was to determine a once-daily well-tolerated...
Grown Rogue Subsidiary Begins Operations in New Jersey
Grown Rogue Subsidiary Begins Operations in New Jersey
Aug 29, 2024
08:05 AM EDT, 08/28/2024 (MT Newswires) -- Grown Rogue International ( GRUSF ) , a craft cannabis company, on Wednesday said subsidiary ABCO Garden State, a licensed cannabis cultivator in New Jersey, began Phase I operations. Phase I includes about 8,000 sq ft of flowering canopy, as measured by bench space, that should produce 500 to 600 pounds of craft...
Copyright 2023-2026 - www.financetom.com All Rights Reserved